Bartha-k61疫苗对生长猪抵抗新发变异伪狂犬病病毒攻击的保护作用
研究采用两种免疫策略评估Bartha-k61疫苗对变异伪狂犬病病毒(PRV)XJ5株和经典PRV Ra株攻击的保护效果,在商品猪中检测体液免疫、临床症状、存活率、体重、排毒和病理。结果显示Bartha-k61疫苗一次或两次接种对变异株XJ5攻击均有效,单次与加强免疫间无显著差异;但经典株Ra攻击后,两次接种猪的体重增长优于一次接种(p<0.01)。
要点
- Bartha-k61疫苗一次或两次接种对变异PRV XJ5株攻击均有效。
- 单次接种与加强接种对变异株攻击的保护效果无显著差异。
- 经典株Ra攻击后,两次接种猪体重增长优于一次接种(p<0.01)。
核心结论
- Bartha-k61疫苗似乎是在缺乏针对这些PRV株的新型强效候选疫苗时控制中国PRV变异株传播的有效疫苗。
研究设计与样本
- 在商品猪中采用两种免疫策略评估Bartha-k61疫苗对变异PRV XJ5株和经典PRV Ra株攻击的保护效果,检测体液免疫应答、临床症状、存活率、体重、排毒和病理。
主要发现
- Bartha-k61疫苗一次或两次接种对变异PRV XJ5株攻击均有效。
- 单次接种与加强接种猪之间无显著差异。
- 经典PRV Ra株攻击后,两次接种猪的体重增长优于一次接种猪(p<0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since late 2011, pseudorabies (PR) has resurfaced in many large pig farms, causing great economic loss for the swine industry in China. The PRV variant strain with high virulence and antigenic variation has been considered to be the main cause, and much attention has been focused on how to prevent and control the reoccurrence of this disease in China. In this study, two kinds of vaccination strategy were employed to evaluate the protective effects of Bartha-k61vaccine against both variant PRV (XJ5) and classical PRV (Ra) strain challenge. Humoral immunity response, clinical signs, survival rate, body weight, virus shedding and pathology were assessed in commercial pigs. The results showed that Bartha-k61vaccine, administered either once or twice, was effective against the PRV variant (XJ5) challenge, while no significant differences were observed between single and prime-boost vaccinated pigs. However, pigs vaccinated twice had better body weight gains than those vaccinated once, following challenge with the classical PRV strain (Ra) (p<0.01). Therefore, the Bartha-k61 vaccine appears to be an effective vaccine to control the spread of PRV variants in China in the absence of new powerful candidate vaccines specific to these PRV strains.
引用
- Zhou J, Li S, Wang X, et al. Bartha-k61 vaccine protects growing pigs against challenge with an emerging variant pseudorabies virus. Vaccine. 2017. PMID: 28131396. doi:10.1016/j.vaccine.2017.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。